M&T Bank Corp Acquires 2,546 Shares of Elevance Health, Inc. $ELV

M&T Bank Corp increased its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 13.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 21,931 shares of the company’s stock after purchasing an additional 2,546 shares during the period. M&T Bank Corp’s holdings in Elevance Health were worth $7,688,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Elevance Health by 0.6% during the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP grew its holdings in Elevance Health by 4.8% during the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after purchasing an additional 303,099 shares during the period. Artisan Partners Limited Partnership grew its holdings in Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC grew its holdings in Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after purchasing an additional 798,457 shares during the period. Finally, Invesco Ltd. grew its holdings in Elevance Health by 22.9% during the third quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after purchasing an additional 484,303 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 0.8%

Shares of ELV stock opened at $369.06 on Wednesday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $424.24. The firm has a 50 day moving average price of $311.21 and a two-hundred day moving average price of $331.78. The company has a market capitalization of $80.15 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 2.12 and a beta of 0.66.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the previous year, the business earned $11.97 earnings per share. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts predict that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is presently 29.26%.

Analyst Ratings Changes

A number of equities analysts recently commented on ELV shares. Jefferies Financial Group reduced their price target on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday, April 20th. Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research report on Tuesday, February 3rd. Wells Fargo & Company cut their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Citigroup upgraded shares of Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Finally, Guggenheim raised their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Thirteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $384.58.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.